Author:
Zarranz-Ventura Javier,Escobar-Barranco José J.,Gómez-Baldó Laia,Gallego-Pinazo Roberto,
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. European Centre for Disease Prevention and Control (ECDC). COVID-19. 2020. https://qap.ecdc.europa.eu/public/extensions/COVID-19/COVID-19.html#global-overview-tab. Accessed 29 Apr 2022.
2. Spanish Government. Real Decreto 463/2020, de 14 de marzo, por el que se declara el estado de alarma para la gestión de la situación de crisis sanitaria ocasionada por el COVID-19. 2020. https://boe.es/boe/dias/2020/03/11/pdfs/BOE-A-2020-3434.pdf#BOEn. Accessed 27 May 2020.
3. Teo KYC, Saxena N, Gan A, et al. Detrimental effect of delayed re-treatment of active disease on outcomes in neovascular age-related macular degeneration: the RAMPS study. Ophthalmology Retina. 2020;4:871–80.
4. Cohen SY, Mimoun G, Oubraham H, et al. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina. 2013;33(3):474–81.
5. Eldem B, Lai TYY, Ngah NF, et al. An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study. Graefes Arch Clin Exp Ophthalmol. 2018;256(5):963–73.